18 Oct 2026
Retina Weekly, 17 Oct 2026: Methotrexate for PVR, Eplerenone and ERM Surgery
Four new retina papers from the past week, with quick, honest takes for ophthalmologists and trainees.
In this episode: - The Cincinnati methotrexate protocol for retinal detachment with PVR grade C (Ophthalmology Retina) - Oral eplerenone in first-episode acute central serous chorioretinopathy: a double-masked randomised trial (International Ophthalmology) - Epiretinal membrane surgery in patients with good visual acuity: a UK multicentre study (Retina) - Cost-effectiveness of the Port Delivery Platform versus aflibercept injections for neovascular AMD (BMC Ophthalmology) - Also mentioned: vessel tortuosity on OCT angiography in MacTel type 2, and serum markers of anti-VEGF response in diabetic macular oedema (Retina) Each paper gets the method, the main result, its strength and limitation, and an evidence label. This episode is for education only. It is not medical advice. Hosted by Mohamed, consultant ophthalmic surgeon. REFERENCES This week's papers 1. Huang D, Feist JE, McTavish SA, et al. Outcomes of complex retinal detachment repair with proliferative vitreoretinopathy grade C using the Cincinnati methotrexate protocol. Ophthalmol Retina. 2026. https://doi.org/10.1016/j.oret.2026.09.030 2. Zamani G, Asghari R, Shoeibi N, et al. Oral eplerenone in first-episode acute central serous chorioretinopathy: results of a double-masked randomized trial. Int Ophthalmol. 2026;46(1). https://doi.org/10.1007/s10792-026-04287-1 3. Jones RL, Feroz L, Lipa RM, et al. Clinical outcomes of epiretinal membrane surgery in patients with good baseline visual acuity. Retina. 2026. https://doi.org/10.1097/IAE.0000000000004976 4. Siekerman MME, Kristiansen IS, Jørstad ØK, et al. Cost-effectiveness of the Port Delivery Platform compared with intravitreal injection of anti-vascular endothelial growth factor for patients with neovascular age-related macular degeneration. BMC Ophthalmol. 2026;26(1). https://doi.org/10.1186/s12886-026-05346-y 5. Bilgeç MD, Karaatlı M, Özalp O, et al. Structural and microvascular alterations in macular telangiectasia type 2: the diagnostic value of vessel tortuosity. Retina. 2026. https://doi.org/10.1097/IAE.0000000000005032 6. Ranga D, Sharma SP, Dogra M, et al. Serum Ang-1, sFLT-1, and sST2 profiles distinguish anti-VEGF responders in diabetic macular edema. Retina. 2026. https://doi.org/10.1097/IAE.0000000000005035 Earlier trials mentioned 7. Lotery A, Sivaprasad S, O'Connell A, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10220):294-303. https://doi.org/10.1016/S0140-6736(19)32981-2 8. Rajan RP, Babu KN, Arumugam KK, et al. Intravitreal methotrexate as an adjuvant in vitrectomy in cases of retinal detachment with proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 2024;263(2):387-391. https://doi.org/10.1007/s00417-024-06665-w 9. Nourinia R, Safi S, Mohammadpour M, et al. Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial. Sci Rep. 2024;14(1):28842. https://doi.org/10.1038/s41598-024-79708-1
